SFA-002 is a first-in-class oral immunomodulator that operates through multiple cellular pathways to treat autoimmune conditions, with an initial focus on mild-to-moderate chronic plaque psoriasis. Unlike current therapies that target single pathways through immunosuppression, SFA-002 works by simultaneously down-regulating multiple pro-inflammatory cytokines including TNF-α, IL-23, IL-10, IL-12, IL-17, and INF-γ, while modulating autoimmune responses. This oral compound has demonstrated promising efficacy in clinical trials, with an excellent safety profile and no observed adverse events. Currently in Phase 1b clinical development, SFA-002 represents a potential paradigm shift in autoimmune disease treatment, offering a multi-targeted approach that could provide patients with a safer, more accessible alternative to current injectable immunosuppressive therapies.